In silico exploration of osteoclast precursor inhibition for preventing rapid bone loss after denosumab discontinuation.

In contrast, subsequent OCPI treatment inhibited osteoclast activity by decreasing osteoclast precursors without directly inhibiting osteoblasts, resulting in an increasing trend in bone volume with an osteoblast-dominant balance.

also in 63,971 other papers

Subsequent alendronate treatment not only inhibited osteoclast activity but also inhibited osteoblast activity, resulting in a decreasing trend in bone volume with an osteoclast-dominant balance.

also in 47,180 other papers